Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma
Zhixuan You(Guangzhou Medical University), Changxuan You(Southern Medical University), Meng Lv(Nanfang Hospital), Xue Hu, Mengli Huang, Yingqin Pan(Nanfang Hospital), Xuanyu He(Nanfang Hospital), Junfeng Ge(Nanfang Hospital), Yating Zheng, Chengzhi Zhou(First Affiliated Hospital of Guangzhou Medical University)
Cited by 16
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
TRPM7 regulates the migration of human nasopharyngeal carcinoma cell by mediating Ca2+ influx
|Cell Calcium|2010|135
CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients
|Biomedicine & Pharmacotherapy|2015|126